Large Vessel Vasculitis:
Giant Cell Arteritis (GCA):
Most common systemic vasculitis with the lifetime risk of 1% in women and half percent in men .
Clinical Features of ANCA Vasculitis:
Additional considerations in ANCA-associated vasculitis:
- The RAVE trial showed similar outcomes between cyclophosphamide and rituximab in nonintubated patients with serum creatinine less than 4. Lowerquality data support use of rituximab without the above exclusions.
- MAINRITSAN trial and its long-term follow-up study showed rituximab superiority to azathioprine in maintenance of remission and improved longterm survival.
- Plasma exchange is commonly used in life-threatening scenarios, however the evidence for its use is not very robust. There is higher-quality evidence for renal disease than the pulmonary hemorrhage. Ongoing trial should provide more guidance soon.
Treatment:
